Drugs News and Research RSS Feed - Drugs News and Research

Changing placebo response dilutes antipsychotic trial power

Changing placebo response dilutes antipsychotic trial power

Factors including patients’ expectations may underlie an increased placebo response in antipsychotic randomised controlled trials published since 1960, say researchers. [More]
Analgesics, anti-inflammatory drugs have beneficial effect on treatment of depression

Analgesics, anti-inflammatory drugs have beneficial effect on treatment of depression

Ordinary over the counter painkillers and anti-inflammatory drugs purchased from pharmacies may also be effective in the treatment of people suffering of depression. [More]
State highlights: Calif. ballot measure updates; Va. prison health care budget shortfall

State highlights: Calif. ballot measure updates; Va. prison health care budget shortfall

A selection of health policy stories from California, Arizona, Maine, South Dakota, Virginia, Maryland, Louisiana, Pennsylvania, Massachusetts, North Carolina, Texas, Washington state and Missouri. [More]
YEDA and XL-protein sign deal to commercialize PASylated IFN superagonis

YEDA and XL-protein sign deal to commercialize PASylated IFN superagonis

YEDA Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science, Israel, and XL-protein GmbH, Germany, a privately owned biopharmaceutical company, have signed a business collaboration agreement to commercialize a PASylated interferon superagonist -- PAS-YNSα8 -- which has been jointly developed by scientists at the Weizmann Institute and XL-protein. [More]
Viewpoints: Health care opponent's legal strategy; the challenge for this open enrollment

Viewpoints: Health care opponent's legal strategy; the challenge for this open enrollment

In 2011 after the first appeals circuit struck down the Affordable Care Act's individual mandate, the White House asked the Supreme Court to take the case as soon as possible and "put these challenges to rest." [More]

ACA knowledge gap greatest among uninsured

Most of the uninsured know little about the online insurance marketplaces, or that financial help is available for those with low incomes, finds a poll. [More]
Study: Automated EEG biofeedback as effective as clinician-run system in addiction treatment

Study: Automated EEG biofeedback as effective as clinician-run system in addiction treatment

An automated EEG biofeedback system works just as well as a clinician-run system in helping reduce attention deficits in those with substance use disorders, according to an independent joint study from researchers at UCLA and UNC Wilmington. [More]
Scientists identify potent inhibitors to combat common obesity gene

Scientists identify potent inhibitors to combat common obesity gene

Individuals who are genetically predisposed to obesity may soon have a therapeutic solution to combat their condition. A research team led by scientists from the National University of Singapore (NUS) has identified several potent inhibitors that selectively target FTO, the common fat mass and obesity-associated gene. [More]
Finding could help improve treatment of hearing loss caused by noise, normal aging

Finding could help improve treatment of hearing loss caused by noise, normal aging

Scientists have restored the hearing of mice partly deafened by noise, using advanced tools to boost the production of a key protein in their ears. [More]
Loyola University Health System to hold medication take-back day

Loyola University Health System to hold medication take-back day

Loyola University Health System will partner with the Cook County Sheriff's Department to hold a medication take-back day. [More]
Obeticholic acid drug shows promise against bile acid diarrhoea

Obeticholic acid drug shows promise against bile acid diarrhoea

A pilot study testing a new type of drug in patients with chronic diarrhoea has shown promising effects on reducing their symptoms. [More]
RegeneRx to begin RGN-259 Phase 3 trials for treatment of neurotrophic keratopathy

RegeneRx to begin RGN-259 Phase 3 trials for treatment of neurotrophic keratopathy

RegeneRx Biopharmaceuticals, Inc. ("the Company" or "RegeneRx") today announced that it met with the FDA in September and as a result of the meeting may begin Phase 3 to evaluate RGN-259 preservative-free eye drops for the treatment of patients with neurotrophic keratopathy (NK), an orphan disease of the cornea. [More]
FDA accepts Eisai's sNDA for perampanel drug for treatment of PGTC seizures

FDA accepts Eisai's sNDA for perampanel drug for treatment of PGTC seizures

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company's Supplemental New Drug Application (sNDA) for its in-house-discovered AMPA receptor antagonist perampanel for the treatment of primary generalized tonic-clonic (PGTC) seizures. [More]
Aspirin can improve efficacy of schizophrenia treatments

Aspirin can improve efficacy of schizophrenia treatments

A new study shows that some anti-inflammatory medicines, such as aspirin, estrogen, and Fluimucil, can improve the efficacy of existing schizophrenia treatments. This work is being presented at the European College of Neuropsychopharmacology conference in Berlin. [More]
Antibiotic-resistant bacteria share resources to cause chronic infections, show studies

Antibiotic-resistant bacteria share resources to cause chronic infections, show studies

Antibiotic-resistant bacteria can share resources to cause chronic infections, Vanderbilt University investigators have discovered. [More]
NIH announces 11 awards to improve public health outcomes related to substance use, addiction

NIH announces 11 awards to improve public health outcomes related to substance use, addiction

More than $11 million over three years will be used to support research exploring the use of social media to advance the scientific understanding, prevention, and treatment of substance use and addiction. [More]
Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications. [More]
Researchers propose new milestones to augment National Alzheimer's Plan

Researchers propose new milestones to augment National Alzheimer's Plan

The U.S. Government has initiated a major effort to prevent and effectively treat Alzheimer's disease by 2025. However, a workgroup of nearly 40 Alzheimer's researchers and scientists says the research milestones in the U.S. Government's National Plan to Address Alzheimer's Disease must be broadened in scope, increased in scale, and adequately funded in order to successfully achieve this goal. [More]
Animal study shows high-fat diet is more harmful to males than females

Animal study shows high-fat diet is more harmful to males than females

Male and female brains are not equal when it comes to the biological response to a high-fat diet. [More]
New drug naming system to be presented at ECNP conference in Berlin

New drug naming system to be presented at ECNP conference in Berlin

What's in a name? Doctors have found that the name of the drug you are prescribed significantly influences how the patient sees the treatment. [More]